Birdwatch Archive

Birdwatch Note

2024-05-26 06:40:43 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

米国国立がん研究所所長(当時)DeVita氏は、がん死亡減少の半分の原因は主に化学療法を含むがん治療の進歩によるものとしています https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 米国の売上上位8位のうちの3つが抗がん剤であり、近年は免疫チェックポイント阻害剤により治療成績も格段に上がっています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 世界の医薬品の売り上げTOP10の半分が抗がん剤です https://answers.ten-navi.com/pharmanews/16470/ WHOは臨床的に有効と証明された必須医薬品リストに抗がん剤が掲載されているとしています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment 年齢調整死亡率で日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 日本人が欧米事情等に疎いことは昔からデマに良く悪用されてきたので注意しましょう https://cancer.jpn.org/static/fake_medicine.html

Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1794595687881129985

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1794619659754557499
  • noteId - 1794619659754557499
  • participantId -
  • noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
  • createdAtMillis - 1716705643964
  • tweetId - 1794595687881129985
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • 米国国立がん研究所所長(当時)DeVita氏は、がん死亡減少の半分の原因は主に化学療法を含むがん治療の進歩によるものとしています https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 米国の売上上位8位のうちの3つが抗がん剤であり、近年は免疫チェックポイント阻害剤により治療成績も格段に上がっています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 世界の医薬品の売り上げTOP10の半分が抗がん剤です https://answers.ten-navi.com/pharmanews/16470/ WHOは臨床的に有効と証明された必須医薬品リストに抗がん剤が掲載されているとしています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment 年齢調整死亡率で日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 日本人が欧米事情等に疎いことは昔からデマに良く悪用されてきたので注意しましょう https://cancer.jpn.org/static/fake_medicine.html

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2024-05-26 06:40:43 UTC
(1716705643964)
2024-05-26 11:41:26 UTC
(1716723686227)
CURRENTLY_RATED_HELPFUL 2024-05-27 04:19:24 UTC
(1716783564296)
CURRENTLY_RATED_HELPFUL 2024-05-26 11:41:26 UTC
(1716723686227)
CURRENTLY_RATED_HELPFUL

Note Ratings

rated at rated by
2024-05-26 18:20:19 -0500 Rating Details
2024-05-26 18:12:06 -0500 Rating Details
2024-05-26 16:55:47 -0500 Rating Details
2024-05-26 10:39:31 -0500 Rating Details
2024-05-26 04:42:34 -0500 Rating Details
2024-05-26 04:01:23 -0500 Rating Details
2024-05-26 03:45:46 -0500 Rating Details
2024-05-26 02:53:08 -0500 Rating Details
2024-05-26 02:43:20 -0500 Rating Details
2024-05-26 02:42:29 -0500 Rating Details
2024-05-26 02:38:20 -0500 Rating Details
2024-05-26 02:34:52 -0500 Rating Details
2024-05-26 02:26:50 -0500 Rating Details
2024-05-26 02:20:37 -0500 Rating Details
2024-05-26 02:09:57 -0500 Rating Details
2024-05-26 02:09:40 -0500 Rating Details
2024-05-26 02:06:41 -0500 Rating Details
2024-05-26 02:03:50 -0500 Rating Details
2024-05-26 02:01:13 -0500 Rating Details
2024-05-26 01:59:14 -0500 Rating Details
2024-05-26 01:58:28 -0500 Rating Details
2024-05-26 01:53:11 -0500 Rating Details
2024-05-26 01:47:33 -0500 Rating Details
2024-05-27 18:09:59 -0500 Rating Details
2024-05-27 08:23:56 -0500 Rating Details
2024-05-26 23:17:18 -0500 Rating Details
2024-05-26 20:42:04 -0500 Rating Details
2024-05-28 12:22:24 -0500 Rating Details
2024-05-28 09:14:25 -0500 Rating Details
2024-05-27 04:32:02 -0500 Rating Details
2024-05-26 22:57:22 -0500 Rating Details
2024-05-26 22:42:27 -0500 Rating Details
2024-05-26 20:21:17 -0500 Rating Details
2024-05-26 18:49:39 -0500 Rating Details
2024-05-26 18:45:29 -0500 Rating Details
2024-05-26 18:18:42 -0500 Rating Details
2024-05-26 18:14:24 -0500 Rating Details
2024-05-26 18:05:39 -0500 Rating Details
2024-05-26 18:04:58 -0500 Rating Details
2024-05-26 05:13:38 -0500 Rating Details
2024-05-26 03:33:49 -0500 Rating Details
2024-05-26 03:33:04 -0500 Rating Details
2024-05-26 03:16:54 -0500 Rating Details
2024-05-26 03:15:12 -0500 Rating Details
2024-05-26 02:59:53 -0500 Rating Details
2024-05-26 02:46:08 -0500 Rating Details
2024-05-26 02:35:58 -0500 Rating Details
2024-05-26 02:29:26 -0500 Rating Details
2024-05-26 02:18:45 -0500 Rating Details
2024-05-26 02:14:22 -0500 Rating Details
2024-05-26 02:07:55 -0500 Rating Details
2024-05-26 02:07:32 -0500 Rating Details
2024-05-26 02:02:12 -0500 Rating Details
2024-05-26 02:01:13 -0500 Rating Details
2024-05-26 01:56:19 -0500 Rating Details
2024-05-26 01:54:30 -0500 Rating Details
2024-05-26 01:52:14 -0500 Rating Details
2024-05-31 11:50:26 -0500 Rating Details
2024-05-27 22:21:37 -0500 Rating Details
2024-05-27 09:57:37 -0500 Rating Details
2024-05-27 04:43:43 -0500 Rating Details
2024-05-27 02:46:16 -0500 Rating Details
2024-05-27 02:15:48 -0500 Rating Details
2024-05-26 22:01:27 -0500 Rating Details
2024-05-26 21:06:10 -0500 Rating Details
2024-05-26 20:38:42 -0500 Rating Details
2024-05-26 19:04:22 -0500 Rating Details
2024-05-26 18:40:52 -0500 Rating Details
2024-05-26 18:32:30 -0500 Rating Details
2024-05-26 18:13:23 -0500 Rating Details
2024-05-26 18:11:30 -0500 Rating Details
2024-05-26 14:07:04 -0500 Rating Details
2024-05-26 10:06:42 -0500 Rating Details
2024-05-26 06:33:04 -0500 Rating Details
2024-05-26 06:29:15 -0500 Rating Details
2024-05-26 05:14:03 -0500 Rating Details
2024-05-26 05:08:56 -0500 Rating Details
2024-05-26 04:12:19 -0500 Rating Details
2024-05-26 03:56:58 -0500 Rating Details
2024-05-26 03:48:54 -0500 Rating Details
2024-05-26 03:39:43 -0500 Rating Details
2024-05-26 03:37:46 -0500 Rating Details
2024-05-26 03:24:40 -0500 Rating Details
2024-05-26 03:18:14 -0500 Rating Details
2024-05-26 03:15:52 -0500 Rating Details
2024-05-26 03:12:54 -0500 Rating Details
2024-05-26 03:02:15 -0500 Rating Details
2024-05-26 02:50:50 -0500 Rating Details
2024-05-26 02:48:53 -0500 Rating Details
2024-05-26 02:44:23 -0500 Rating Details
2024-05-26 02:42:35 -0500 Rating Details
2024-05-26 02:31:56 -0500 Rating Details
2024-05-26 02:18:29 -0500 Rating Details
2024-05-26 02:08:36 -0500 Rating Details
2024-05-26 02:07:21 -0500 Rating Details
2024-05-26 01:47:49 -0500 Rating Details
2024-05-26 01:45:12 -0500 Rating Details
2024-05-26 01:42:07 -0500 Rating Details
2024-05-27 01:24:52 -0500 Rating Details
2024-06-03 20:56:54 -0500 Rating Details
2024-05-27 05:05:10 -0500 Rating Details